Interference in thyroid hormones with Roche immunoassays: an unfinished story

Zaninotto, Martina; Tognon, Costanza; Venturini, Roberta; Betterle, Corrado; Plebani, Mario

doi:10.1515/cclm-2014-0454

Cited by 15 publications

(10 citation statements)

References 8 publications

(9 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because the analytic error was method specific, the sources of signal suppression particular to the Roche methodology were reviewed. These sources include high-dose biotin supplementation (>5 mg/day) or endogenous antibodies including those binding to ruthenium or streptavidin (1,2,(4)(5)(6)(7). High-dose biotin therapy is used for a number of purposes including the treatment of deficiencies in select inborn errors of metabolism (e.g., biotinidase deficiency), as a nutritional…”

Section: Discussionmentioning

confidence: 99%

Grave Clinicopathologic Correlation: A Case of Hyperthyroxinemia

Mattman

DeMarco

Wong

et al. 2016

The Journal of Applied Laboratory Medicine

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Grave Clinicopathologic Correlation: A Case of Hyperthyroxinemia

Mattman

DeMarco

Wong

et al. 2016

The Journal of Applied Laboratory Medicine

View full text Add to dashboard Cite

“…To our knowledge, it is the first published report of such interferences other than the well known anti-ruthenium antibodies [5] or unidentified [6] with the Cobas assays. The discrepancies obtained with Roche assays can be explained by the use of streptavidin-labeled magnetic particle to which biotin (coupled with exo genous hormone, autoantibody or a TSH-specific antibody) would bind.…”

mentioning

confidence: 90%

“…Moreover, anti-TPO and anti-Tg evaluated on the Kryptor ® Compact plus (Thermofischer) and anti-TSHR determined using the RIA human TRAK assay (Thermofischer) were found negative. Thus, assay interferences in the Cobas ® thyroid results, often reported in Brought to you by | Carleton University OCUL Authenticated Download Date | 7/15/15 7:22 AM the literature [5,6], were suspected and patient treatment with Thiamazol was stopped. Patient's consent was obtained for measuring serum thyroid parameters using other methods.…”

mentioning

confidence: 99%

Anti-streptavidin interferences in Roche thyroid immunoassays: a case report

Peltier¹,

Massart²,

Moineau³

et al. 2016

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

show abstract

“…However, many laboratory-related diagnostic errors described in the literature are linked to this type of error [4][5][6][7][8][9][10][11][12][13][14]. Not only do they exist, but they also incur a risk of adverse events and harm for patients, and faults in diagnostic-therapeutic pathways.…”

mentioning

confidence: 99%

Analytical quality: an unfinished journey

Plebani

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

Self Cite

View full text Add to dashboard Cite

In laboratory medicine, a great forward step has been taken toward the pathway to a better understanding of quality, errors and risks to patient safety. An innovative approach for identifying all possible analytical errors, and systematically evaluating errors in individual patient results, is described in the paper by Michael Vogeser and Christoph Seger "Irregular analytical errors in diagnostic testing -a novel concept", in the current issue of the journal [1].A valuable source of information and a topic for further discussion, the paper (a) focuses on the need for a patient-centered approach for evaluating analytical quality; (b) reinforces the utility of appropriate metrics for measuring and improving upon quality in the analytical phase of laboratory testing; (c) stresses the importance of adequately defining the uncertainty of laboratory results and related "allowable uncertainty"; (d) stresses that a closer clinical-laboratory interface relationship, particularly in the post-post-analytical phase, is needed for adequately identifying the nature of "irregular (individual) analytical errors" -and providing valuable explanations and defining any corrective actions required; (e) is conducive to including the monitoring of "irregular analytical errors" as an additional quality indicator of the IFCC model of the quality indicator (MQI) project [2][3][4].The authors state that an "irregular analytical error is given when a test result generated from a sample using a routine method deviates from the reference measurement procedure (RMP) results generated for this sample more than the measurement error estimate of the routine method" [1]. They also state that an irregular analytical error should be generated, particularly in immunoassays, by: a cross-reaction, sometimes with compounds not listed by the manufacturer; anti-reagent antibodies (e.g. heterophilic antibodies); interference in signalgeneration (e.g anti-ruthenium antibodies); high levels of compounds (e.g. biotin in streptavidin/biotin binding-based immunoassays); matrix protein interferences (e.g. due to immunocomplexes, rheumatoid factors) and several other matrix effects (e.g. differential impact of matrix factors on target analyte and internal standard in LC-MS assays).

show abstract

Interference in thyroid hormones with Roche immunoassays: an unfinished story

Cited by 15 publications

References 8 publications

Grave Clinicopathologic Correlation: A Case of Hyperthyroxinemia

Grave Clinicopathologic Correlation: A Case of Hyperthyroxinemia

Anti-streptavidin interferences in Roche thyroid immunoassays: a case report

Analytical quality: an unfinished journey

Contact Info

Product

Resources

About